Russian MedicineRussian MedicineРоссийский медицинский журнал0869-21062412-9100Eco-Vector3839410.18821/0869-2106-2017-23-1-40-45ArticlesСтатьиResearch ArticleThe possibilities of medicinal therapy in patients with calcined aortic stenosisВозможности медикаментозной терапии у больных с кальцинированным аортальным стенозомAndropovaOlesya V.АндроповаО. В

candidate of medical sciences, cardiologist of cardiology department of polyclinic № 1 of the executive office of the President of the Russian Federation

канд. мед. наук, врач-кардиолог кардиологического отделения ФГБУ «Поликлиника № 1» УД Президента РФ

o.andropova@vipmed.ruAlekseevaL. AАлексееваЛ. АMinushkinaL. OМинушкинаЛ. ОThe polyclinic №1 of the executive office of the President of the Russian FederationФГБУ «Поликлиника №1» УД Президента РФThe educational research center of the executive office of the President of the Russian FederationФГБУ «Учебно-научный медицинский центр» УД Президента РФ15022017231VOL 23, NO1 (2017)ТОМ 23, №1 (2017)404521072020Copyright ©; 2017, Eco-VectorCopyright ©; 2017, ООО "Эко-Вектор"2017Eco-VectorООО "Эко-Вектор"https://medjrf.com/0869-2106/article/view/38394

The calcined aortic stenosis is one of the most frequently occurring cardio-vascular diseases with unfavorable prognosis of treatment. Te actual conceptions of risk factors of development, pathogenesis and course of disease starting from inflammation and endothelial dysfunction and completing with bone metaplasia give an opportunity of determining prospective directions of medicinal therapy favoring deceleration of progressing of calcined aortic stenosis. The review summarizes main data of publications concerning attempts of pathogenetically medicinal impact on progressing of calcined aortic stenosis.

Кальцинированный аортальный стеноз (КАС) - одно из самых часто встречающихся сердечно-сосудистых заболеваний с неблагоприятным прогнозом течения. Современные представления о факторах риска развития, патогенезе и течении заболевания, начинающегося с воспаления и эндотелиальной дисфункции и завершающегося костной метаплазией, дают возможность определить перспективные направления лекарственной терапии, способствующей замедлению прогрессирования КАС. В обзоре суммированы основные данные литературы о попытках патогенетически обоснованного медикаментозного воздействия на прогрессирование КАС.

reviewcalcined aortic stenosismedicinal therapystatinsblockers of renin-angiotensin-aldosterone systemкальцинированный аортальный стенозмедикаментозная терапиястатиныблокаторы ренин-ангиотензин-альдостероновой системыEveborn G.W., Schirmer H., Heggelund G., Lunde P., Rasmussen K. The evolving epidemiology of valvular aortic stenosis. The Tromsö Study. Heart. 2013; 99(6): 396-400.Сarabello B.A. Evaluation and management of patients with aortic stenosis. Circulation. 2002; 105(15): 1746-50.Braunwald E. Heart Disease: a Textbook of Cardiovascular Medicine: 9-th ed. Philadelphia; 2012.Pierri H., N ussbacher A., Décourt L.V., Medeiros C., Cattani A., Serro-Azul J.B. et al. Clinical predictors of prognosis in severe aortic stenosis in unoperated patients > or = 75 years of age. Am. J. Cardiol. 2000; 86(7): 801-4, A10.PARTNER Investigators Announce Dramatic Trial Results for the Treatment of Aortic Stenosis. Available at: http://www.mayoclinic.org/documents/mc2024-0111-pdf/doc-20078912Otto C.M., Prendergast B. Aortic-Valve Stenosis - From Patients ar Risk to Severe V alve O bstruction. N. Engl. J. Med. 2014; 371: 744-56.Dweck M.R., Boon N.A., David E. Newby D.E. Calcific aortic stenosis: a disease of the valve and the myocardium. J. Am. Coll. Cardiol. 2012; 60(19): 1854-63.Rajamannan N.M., Evans F.J., Aikawa E., Grande-Allen K.J., Demer L.L., H eistad D.D. et al. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National H eart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011; 124(16): 1783-91.Hutcheson J.D., Aikawa E., Merryman D. Potential drug targets for calcific aortic valve disease. Nat. Rev. Cardiol. 2014; 11(4): 218-31.Salas M.J., Santana O ., Escolar E., Lamas G.A. Medical T herapy for Calcific Aortic Stenosis. J. Cardiovasc. Pharmacol. Ther. 2012; 17(2): 133-8.Otto C.M., Gaasch W.H., Yeon S.B. Medical management of asymptomatic aortic stenosis in adults. Available at: http://www.uptodate.com/contents/medical-management-of-asymptomatic-aortic-stenosis-in-adults.Mohler E.R. 3rd, Wang H., Medenilla E., Scott C. Effect of Statin Treatment on Aortic V alve and Coronary Artery Calcification. J. Heart Valve Dis. 2007; 16(4): 378-86.Novaro G.M., Tiong I.Y., Pearce G .L., Lauer M.S., Sprecher D.L., Griffin B.P. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104(18): 2205-9.Shavelle D.M., T akasu J., Budoff M.J. Mao S., Zhao X.Q., O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359(9312): 1125-6.Bellamy M.F., Pellikka P.A., Klarich K.W., T ajik A.J., Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment and progression of aortic stenosis in the community. J. Am. Coll. Cardiol. 2002; 40(10): 1723-30.Rosenhek R., Rader F., Loho N., Gabriel H., H eger M., Klaar U. et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110(10): 1291-5.Kuwabara M., Kitaoka H., Okawa M., Furuno T., Nishinaga M., Doi Y. Treatment with HMG-CoA reductase inhibitors (statins) attenuates the progression of aortic valve stenosis in the elderly. Geriatr. Gerontol. Int. 2006; 6: 124-8.Antonini-Canterin F., Hîrşu M., Popescu B.A., Leiballi E., Piazza R., Pavan D. et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am. J. Cardiol. 2008; 102(6): 738-42.Drolet M.C., Arsenault M., Couet J. Experimental aortic valve stenosis in rabbits. J. Am. Coll. Cardiol. 2003; 41(7): 1211-7.Rajamannan N.M., Subramaniam M., Springett M., Sebo T.C., Niekrasz M., McConnell J.P. et al. Atorvastatin inhibits hypercholesterinemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002; 105: 2660-5.Rossebø A.B., Pedersen T .R., Boman K., Brudi P., Chambers J.B., Egstrup K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 2008; 359 (13): 1343-56.Cowell S.J., N ewby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B. et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 2005; 352(23): 2389-97.Chan K.L., Teo K., Dumesnil J.G., Ni A., Tam J., ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010; 121(2): 306-14.Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P. 3rd, Guyton R.A. et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice G uidelines. J. Am. Coll. Cardiol. 2014; 63(22): 2438-88.Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F., Rocha-Gonçalves F. et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol. 2007; 49(5): 554-61.Moura L.M., Ramos S.F., Kristensen S.D., Pinto F.J., Barros I.M., Rocha-Gonçalves F. Rosuvastatin slows the development of diastolic dysfunction in calcific aortic stenosis. J. Heart Valve Dis. 2012; 21(4): 463-72.Kuhn E.W., Liakopoulos O.J., Stange S., Deppe A.C., Slottosch I., Scherner M. et.al. Meta-analysis of patients taking statins before revascularization and aortic valve surgery. Ann. Thorac. Surg. 2013; 96(4): 1508-16.Vahanian A., Alfieri O., Andreotti F., Antunes M.J., Barón-Esquivias G., Baumgartner H. et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of V alvular H eart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. J. Cardiothorac. Surg. 2012; 42(4): S1-44.Otto C.M. Aortic stenosis - listen to the patient, look at the valve. N. Engl. J. Med. 2000; 343(9): 652-4.Otto C.M. Calcific aortic stenosis - time look more closely at the valve. N. Engl. J. Med. 2008; 359(13): 1395-8.O’Brien K.D., Probstfield J.L., Caulfield M.T., Nasir K., T akasu J., Shavelle D.M. et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch. Intern. Med. 2005; 165(8): 858-62.Katsi V., Marketou M., Kallistratos M.S., Makris T., Manolis A.J., Tousoulis D. et al. Aortic Valve Stenosis and Arterial H ypertension. Curr. Hypertens. Rep. 2013; 15(4): 298-303.Ferrari G., Sainger R., Beckmann E., Keller G., Yu P.J., Monti M.C. et al. Validation of plasma biomarkers in degenerative calcific aortic stenosis. J. Surg. Res. 2010; 163(1): 12-7.O’Brien K.D., Zhao X.Q., Shavelle D.M., Caulfield M.T., Letterer R.A., Kapadia S.R. et al. H emodynamic effects of the angiotensinconverting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J. Investig. Med. 2004; 52(3): 185-91.Caulfield M.T., Budoff M.J., T akasu J. Angiotensin converting enzyme inhibitor is associated with a decreased rate of aortic valve calcium accumulation. Circulation. 2002; 106(Suppl.2): 640.Ngo D.T., Stafford I., Sverdlov A.L., Qi W., Wuttke R.D., Zhang Y. et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br. J. Pharmacol. 2011; 162(3): 722-32.Wakabayashi K., Tsujino T ., Naito Y ., Ezumi A., Lee-Kawabata M., Nakao S. et al. Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. Heart Vessels. 2011; 26(3):252-7.Dahl J.S., Videbaek L., Poulsen M.K., Pellikka P.A., Veien K., Andersen L.I. et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am. J. Cardiol. 2010; 106(5): 713-9.Bull S., Loudon M., Francis J.M., Joseph J., Gerry S., Karamitsos T.D. et al. A prospective, double-blind, randomised controlled trial of the angiotensin converting enzyme inhibitor Ramipril in Asymptomatic Aortic Stenosis (RIAS trial): trial protocol. J. Clin. Trials. 2014; 4: 151.Dalsgaard M., Iversen K., Kjaergaard J., Grande P., Goetze J.P., Clemmensen P. et al. Short-term hemodynamic effect of angiotensinconverting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. Am. Heart J. 2014; 167(2): 226-34.Nadir M.A., Wei L., Elder D.H., Libianto R., Lim T.K., Pauriah M. et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J. Am. Coll. Cardiol. 2011; 58(6): 57-6.Skolnick A.H., Martin Osranek M., Formica Ph., Kronzon I. O steoporosis treatment and progression of aortic stenosis. Am. J. Cardiol. 2009; 104(1): 122-4.Sterbakova G ., Vaclav Vyskocil V., Linhartova K. Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease - a pilot retrospective study. Cardiology. 2010; 117(3): 184-9.Elmariah S., Delaney J.A.C., O’Brien K.D., Budoff M.J., Vogel-Claussen J., Fuster V. et al. Bisphosphonate U se and prevalence of Valvular and V ascular Calcification in Women. MESA (The Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2010; 56(21): 1752-9.Innasimuthu A.L., Katz W.E. Effect of bisphosphonates on the progression of degenerative aortic stenosis. Echocardiography. 2011; 28(1): 1-7.The Potential of Candesartan to Retard the Progression of Aortic Stenosis (ROCK-AS). Available at: http://clinicaltrial.gov/ct2/show/NCT00699452.ARandomized T rial of Angiotensin Receptor Blocker, Fimasartan, in Aortic Stenosis (ALFA T rial). Available at: http://clinicaltrial.gov/ct2/show/NCT01589380.Effect of Bisoprolol on Progression of Aortic Stenosis (BLAST). Available at: http://clinicaltrial.gov/ct2/show/NCT01579058Myocardial Efficiency of the Left V entricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention? (MELVAS). Available at: http://clinicaltrial.gov/ct2/show/NCT02076711.Study Investigating the Effect of Drugs Used to Treat O steoporosis on the Progression of Calcific Aortic Stenosis (SALTIRE II and RANKL Inhibition in Aortic Stenosis). Available at: http://clinicaltrial.gov/ct2/show/NCT02132026.Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis. Available at: http://clinicaltrial.gov/ct2/show/NCT02049203.Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL). Available at: http://clinicaltrial.gov/ct2/show/NCT02109614.